“that's going to be the other dynamic here to be able to move our diagnostic business from being you know, kind of low single digit growth, to now kind of mid single mid to high single digit growth next year.”

In context

“ng to say that it's fully back, but I'm I'm encouraged to see some of the signs, start to pick up in terms of volume there. And if you look at how that happened to us, it really started happening in Q4 of last year. So we'll start to see a little bit of that headwind kind of that comp start to be minimized in Q4 This Year In China. And then next year, like I said, we've made changes. We've brought in new products, new management teams, etcetera. And I feel good about what I saw there last week, David. So I don't think that that's changing. And like I said, I think that's not a bad thing. We'll be lapping all of that, and we're seeing nice progress there. From the team too. I do think that the aspect that is changing is we are seeing our business outside of China continue to accelerate and that's going to be the other dynamic here to be able to move our diagnostic business from being you know, kind of low single digit growth, to now kind of mid single mid to high single digit growth next year. U. S. Has done incredibly well. I give a lot of kudos to the team there. They were up 10% this quarter. And that's driven by a lot of new business capture. So again, portfolio is very competitive. We got a large number of new business that we we last year, and continue to see new business converting to Abbott Laboratories this year. So I think share gains in The U. S. Is really what's driving that. European region did very well too. The quarter. I think they were up six to 7% they're doing very well also. Then Latin America, for us is, you know, growing mid teens, consistently growing mid teens here also. So I think the dynamic is not changing. So we're not seeing the situation get get worse in China. And I think the teams are doing really well there. We'll be out of that next year and ou”